Pharmaceutical companies have historically had to rely on animal models and human observation to identify promising drug candidates for later testing. That approach has left much room for error and unpredictability, which slowed down the development process and raised costs. Thanks to advancements in genomics, pharmaceutical companies can significantly reduce the time and cost of their R&D cycles by looking ...